ESMO 2026 LBA | EGFR×HER3 Bispecific ADC Iza-bren Reshapes the Treatment Landscape of Advanced HR+/HER2− Breast Cancer, Becoming the First Chinese Innovative Drug in Breast Cancer to Be Published in The Lancet
From October 23 to 27, 2026, the European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain. At the meeting, iza-bren (BL-B01D1), an innovative EGFR×HER3 bispecific antibody–drug conjugate (BsADC) independently developed by SystImmune, made a remarkable appearance with data from its pivotal Phase III PANKU-Breast01 study. As a first-in-class, new-concept therapeutic, the agent's prespecified interim analysis results were presented in full for the first time worldwide in a late-breaking abstract (LBA).








